C8759
Carisoprodol
别名:
2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C12H24N2O4
化学文摘社编号:
分子量:
260.33
UNSPSC Code:
12352200
PubChem Substance ID:
EC Number:
201-118-7
MDL number:
InChI key
OFZCIYFFPZCNJE-UHFFFAOYSA-N
InChI
1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)
SMILES string
CCCC(C)(COC(N)=O)COC(=O)NC(C)C
drug control
USDEA Schedule IV
solubility
ethanol: soluble
originator
Schering Plough
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
General description
Carisoprodol (N-isopropyl-2-methyl-2-propyl-l,3-propanediol dicarbamate) is a dicarbamate that is structurally similar to mephenesin and meprobamate. It functions as a skeletal muscle relaxant and has analgesic properties. Although it does not have an effect on behavior, it inhibits reticular formation. The area associated with pain perception in the CNS is affected by carisoprodol for its analgesic activity.
Carisoprodol is actively metabolized to meprobamate, a depressant of the CNS having sedative hypnotic.
Carisoprodol is actively metabolized to meprobamate, a depressant of the CNS having sedative hypnotic.
Application
Carisoprodol has been used as a standard for quantitative determination of carisoprodol in tablets using high-performance thin-layer chromatography. It has also been used to study the effect of pharmacological agents on the muscles of dystrophin-deficient mdx5Cv mice.
Biochem/physiol Actions
Metabolite of meprobamate that is a skeletal muscle relaxant, reduces muscle spasm by depression of brainstem neurons.
Features and Benefits
This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
法规信息
新产品
此项目有
Laxmaiah Manchikanti et al.
Pain physician, 16(1), E1-E13 (2013-01-24)
Reports of chronic pain and associated opioid use, abuse, and fatalities continue to increase at an alarming rate, not only in the United States but also across the globe. In light of the many resultant fatalities, multiple authors and authorities
James P Zacny et al.
Drug and alcohol dependence, 120(1-3), 229-232 (2011-08-16)
Some chronic pain patients on long-term opioid therapy also take centrally active skeletal muscle relaxants. One of those muscle relaxants is carisoprodol, a drug that is abused and capable of producing impairment. It would be of relevance to characterize the
Jennifer A Fass
The Annals of pharmacotherapy, 44(12), 1962-1967 (2010-11-11)
To review the current legal status and patterns of abuse of carisoprodol. A literature search was conducted through MEDLINE (1950-August 2010), PubMed (1966-August 2010), EMBASE (1966-August 2010), and International Pharmaceutical Abstracts (1970-August 2010) using the search terms carisoprodol and abuse.
J G Bramness et al.
Clinical pharmacology and therapeutics, 91(3), 438-441 (2012-02-10)
Carisoprodol, a centrally acting muscle relaxant indicated for acute lower back pain, has been available in Europe and the United States since 1959. Studies indicating increased risk of abuse or addiction led to withdrawal of the drug from the market
James P Zacny et al.
Pharmacology, biochemistry, and behavior, 100(1), 138-143 (2011-09-03)
Carisoprodol is a centrally acting drug used to relieve skeletal muscle spasms and associated pain in acute musculoskeletal conditions. There is evidence from different sources that this oral muscle relaxant is abused and that it is associated with impairment leading
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持